Atsena Advances XLRS Gene Therapy

Atsena Therapeutics dose first patient in pivotal XLRS gene therapy trial

June 30, 2026
2 min

The Ophthalmologist

Overview

Atsena Therapeutics has initiated dosing in the Phase 3 LIGHTHOUSE trial for ATSN-201, a gene therapy targeting X-linked retinoschisis (XLRS). The trial aims to enroll 76 patients and evaluate the therapy's impact on retinal function over 52 weeks.

Background

X-linked retinoschisis (XLRS) is a rare inherited retinal disease primarily affecting males, leading to progressive vision loss and blindness. Currently, there are no approved treatments for XLRS.

Data Highlights

No numerical data available in the source material.

Key Findings

The LIGHTHOUSE trial is a Phase 3 study evaluating ATSN-201 for XLRS.
Enrollment began in May 2023 and has reached 10% of the target population.
The trial will randomize participants to receive ATSN-201 or enter a control arm for 12 months.
The primary endpoint is change in microperimetry at 52 weeks.
Phase 1/2 data indicated that ATSN-201 could reverse structural retinal damage.
A Biologics License Application is targeted for the second half of 2028.

Clinical Implications

The initiation of the LIGHTHOUSE trial highlights the urgent need for effective treatments for XLRS. As the trial progresses, it may provide valuable insights into the efficacy and safety of gene therapy in this patient population.

Conclusion

The advancement of ATSN-201 through clinical trials represents a potential breakthrough in the treatment of X-linked retinoschisis, addressing a significant unmet medical need.